Depomed pays over $1 billion for US rights to Janssen's Nucynta franchise
US specialty drugmaker Depomed (Nasdaq: DEPO) has entered into a definitive agreement to acquire the US rights to the Nucynta (tapentadol) franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, for $1.05 billion.
The franchise includes Nucynta ER extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and Nucynta, an immediate release version of tapentadol, for management of moderate to severe acute pain in adults.
The deal will make Nucynta the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals. Depomed expects to support Nucynta and Nucynta ER with an expanded sales force of over 250 representatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze